Targeted Oncology· @TargetedOnc · X·· 1 day agoScore70
Body · original
Where does KEYNOTE-B49 fit in today’s rapidly evolving breast cancer landscape?
With ADCs and biomarker-directed therapies reshaping HR+/HER2− metastatic disease, is adding pembrolizumab to chemotherapy still a compelling strategy?
#ESMO26 #BreastCancer
59 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com